Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia
Completed · Phase 3 · Has a placebo group
Conditions studied: Sleep Initiation and Maintenance Disorders, Insomnia
In brief
The aim of the study is to confirm the efficacy of eplivanserin 5mg/day on sleep maintenance of patients with primary insomnia using night polysomnography recordings over a 6-week treatment period corresponding to a stabilization of improvement of sleep.
Key facts
- Study ID
- NCT00308503
- Run by
- Sanofi
- People needed
- 608
- Starts
- 2006-02-01
- Expected to finish
- 2007-08-01
- Last updated by the study team
- 2010-11-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for at least one month preceding the study visit.
- Disturbance of sleep maintenance:
- Based on patient' s information:
- Patient has spent at least 6.5 hours and not more than 9.0 hours, in bed, each night, over the preceding two weeks,
- Patient must complain of at least one hour of wakefulness after sleep onset for at least 3 nights per week over the preceding month,
- Patient must report impact on daytime functioning associated with sleep maintenance insomnia
- Inclusion will be based on the nocturnal polysomnography (NPSG) recordings performed at the sleep laboratory during the two screening nights.
You may not qualify if…
- Females who are lactating or who are pregnant, or of childbearing potential not using an acceptable form of contraception
- Patients presenting with acute or chronic pain resulting in insomnia
- Patients with current psychiatric disturbances
- Body mass index > 32
- Evidence of any clinically significant, severe or unstable, acute or chronically progressive medical or surgical disorder, or any condition that may interfere with the absorption, metabolism, distribution or excretion of the study drug, or may affect patient safety
- Clinically significant and abnormal electrocardiogram (ECG) (including QTc B > 500ms),
- A positive test for hepatitis B (hepatitis B surface [HBs] antigens) or C (hepatitis C virus [HCV] antibodies)
- Positive qualitative urine drug screen at screening
- Consumption of xanthine-containing beverages (i.e. tea, coffee, or cola) comprising usually more than 5 cups or glasses per day
- Use of any over-the-counter or prescription sleep medication, or of any substance with psychotropic effects or properties known to affect sleep/wake, within one week or five half-lives (whichever is longer), prior to screening
- Night shift workers, and individuals who nap 3 or more times per week over the preceding month
- Based on medical history and/or NPSG:
- primary hypersomnia
- narcolepsy
- breathing-related sleep disorder (apnea-hypopnea index > 10/hour of sleep)
- circadian rhythm sleep disorder
- parasomnia (e.g. somnambulism)
Where it is running
- Sanofi-Aventis — Bridgewater, New York, United States
- Sanofi-Aventis — Macquarie Park, New South Wales, Australia
- Sanofi-Aventis — Laval, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.